Cargando…

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

BACKGROUND: Revefenacin is a long-acting muscarinic antagonist that was recently approved for the nebulized treatment of chronic obstructive pulmonary disease (COPD). Although shorter duration studies have documented the efficacy of revefenacin in COPD, longer-term efficacy has not been described. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donohue, James F., Kerwin, Edward, Sethi, Sanjay, Haumann, Brett, Pendyala, Srikanth, Dean, Lorna, Barnes, Chris N., Moran, Edmund J., Crater, Glenn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822411/ https://www.ncbi.nlm.nih.gov/pubmed/31666076 http://dx.doi.org/10.1186/s12931-019-1187-7

Ejemplares similares

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
por: Donohue, James, et al.
Publicado: (2019)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
por: Donohue, James F., et al.
Publicado: (2020)

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease
por: Pudi, Krishna K., et al.
Publicado: (2017)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019)

Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Correction to: Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2019)

The Role of Revefenacin in Chronic Obstructive Pulmonary Disease
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
por: Doherty, Dennis E, et al.
Publicado: (2012)

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study
por: Donohue, James F, et al.
Publicado: (2014)

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
por: Tashkin, Donald P, et al.
Publicado: (2012)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
por: Kerwin, Edward M., et al.
Publicado: (2019)

Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease
por: Lo, Arthur, et al.
Publicado: (2020)

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials
por: Tashkin, Donald P, et al.
Publicado: (2012)

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial
por: Donohue, James F, et al.
Publicado: (2018)

The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review
por: Zhang, Jiaxing, et al.
Publicado: (2021)

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52
por: Johnson, Travis, et al.
Publicado: (2023)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective
por: Singh, Dave, et al.
Publicado: (2019)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
por: Sethi, Sanjay, et al.
Publicado: (2019)

Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
por: Yang, Ting, et al.
Publicado: (2023)

Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2022)

Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
por: Hvisdas, Christopher
Publicado: (2021)

Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)
por: Yang, Ting, et al.
Publicado: (2023)

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
por: Singh, Dave, et al.
Publicado: (2021)

Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
por: Dalal, Anand A, et al.
Publicado: (2012)

Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD
por: Dalal, Anand A, et al.
Publicado: (2012)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Creative 52: weekly projects to invigorate your photography portfolio
por: Adler, Lindsay
Publicado: (2014)

DNA methylation changes in infants between 6 and 52 weeks
por: Wikenius, Ellen, et al.
Publicado: (2019)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

A Year with Peter Drucker - 52 Weeks of Coaching for Leadership Effectiveness
por: Maciariello, Joseph
Publicado: (2014)

52nd Rencontres de Moriond on Very High Energy Phenomena in the Universe
por: Auge, Etienne, et al.
Publicado: (2017)

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial
por: Lötvall, J, et al.
Publicado: (2012)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
por: D’Urzo, Anthony D, et al.
Publicado: (2014)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
por: Singh, Dave, et al.
Publicado: (2019)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
por: Kerwin, Edward M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m95thel1u0ri2or0leipnrbpi6